Multi-Centre, Open-Label Extension Trial of Treatment With ZD1839 (Iressa) in Patients Who Have Been Treated in Other ZD1839 Clinical Trials and May Benefit From Continued Monotherapy ZD 1839.
Phase 3
18 Years
N/A
18 Years
N/A
Not Enrolling
Both
Cancer
Both
Cancer
Trial Information
Multi-Centre, Open-Label Extension Trial of Treatment With ZD1839 (Iressa) in Patients Who Have Been Treated in Other ZD1839 Clinical Trials and May Benefit From Continued Monotherapy ZD 1839.
Inclusion Criteria:
- Received treatment in a previous Iressa clinical trial
- Provided Informed Consent to participate in the trial
- 30 days or less since completing the previous Iressa trial.
Exclusion Criteria:
- Radiotherapy completed more than 14 days before starting treatment in this trial
- Incomplete healing from prior surgery
- Withdrawal from previous Iressa trial due to unacceptable toxicity to major organs
Type of Study:
Interventional
Study Design:
Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Outcome Measure:
Adverse Events
Outcome Time Frame:
Every 28 days
Authority:
United States: Food and Drug Administration
Study ID:
1839IL/0026
NCT ID:
NCT00635973
Start Date:
February 2000
Completion Date:
October 2003
Related Keywords:
- Cancer
- Iressa
- Gefitinib
- Cancer
- Patients diagnosed with cancer who have previously received Iressa in an Iressa clinical trial
Name | Location |
|---|
